Company intelligence / Profile preview
Miltenyi Biomedicine GmbH
Bergisch Gladbach, Germanymiltenyibiomedicine.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Positive interim results from DALY II USA, a pivotal Phase II trial investigating zamtocabtagene autoleucel (zamto-cel) in patients with third line, relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) were presented at the American Society of Hematology (ASH) Annual Meeting on December 7, 2024. The pre-planned interim analysis showed that zamto-cel has a favorable safety profile and promising overall response.[8]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Cell therapyGene therapyCAR T cell therapy
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Miltenyi Biomedicine GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Miltenyi Biomedicine GmbH.